Episode 4: "No way back"
The reaction inside PMI after André Calantzopoulos, our then CEO, publicly announced that the company will phase out cigarettes. Also, we discuss our historic FDA application to authorize IQOS as a modified risk tobacco product.
Our progress toward a smoke-free future as of Q3 2024
1 As of June 30, 2024. 2 As of December 31, 2023. Important Note: This information should be read in conjunction with the Philip Morris International Inc. earnings release dated October 22, 2024, as well as the accompanying glossary of key terms, definitions, explanatory notes, select financial information and reconciliations of non-GAAP financial measures, both of which are available on our Investor Relations pages. “PMI” refers to Philip Morris International Inc. and its subsidiaries.
Watch: In the spotlight
Why invest in PMI?
We are investing behind innovation and delivering sustainable growth from our leading smoke-free products, which are a much better choice than continued smoking.
Share Price PM (Common Stock)
$12378
0.00 (0%)
Latest news & press releases
Media Center-
Philip Morris International Reports 2024 Third-Quarter & First Nine-Months Results; Raises 2024 Guidance for Reported Diluted EPS to $6.20 - $6.26 and Adjusted Diluted EPS to $6.45 - $6.51
-
Court-Appointed Mediator Proposes CCAA Plan to Resolve Tobacco Product-Related Claims and Litigation in Canada
-
Philip Morris International to Host Webcast of 2024 Third-Quarter and First Nine-Months Results
-
Vectura Fertin Pharma, Inc., a Subsidiary of Philip Morris International, Announces Agreement for Sale of Vectura Group to Molex
This site is operated for the purpose of providing general information about us. The site is not operated for advertising or marketing purposes. The material on this site should not be regarded as an offer to sell, or a solicitation of an offer to buy, any product of PMI. Such products are sold only in compliance with the laws of the particular jurisdictions in which they are sold.